BioCryst Pharmaceuticals, Inc. (BCRX)
NASDAQ: BCRX · Real-Time Price · USD
7.57
+0.18 (2.44%)
At close: Dec 20, 2024, 4:00 PM
7.63
+0.06 (0.79%)
After-hours: Dec 20, 2024, 6:00 PM EST
BioCryst Pharmaceuticals Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for BCRX stock have an average target of 15.6, with a low estimate of 8.00 and a high estimate of 30. The average target predicts an increase of 106.08% from the current stock price of 7.57.
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 5, 2024.
Analyst Ratings
The average analyst rating for BCRX stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 2 | 2 | 2 | 2 | 2 |
| Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Hold | 0 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 6 | 6 | 6 | 6 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Reiterates $10 | Buy | Reiterates | $10 | +32.10% | Nov 5, 2024 |
| Needham | Needham | Strong Buy Reiterates $14 | Strong Buy | Reiterates | $14 | +84.94% | Nov 5, 2024 |
| Barclays | Barclays | Hold Maintains $7 → $8 | Hold | Maintains | $7 → $8 | +5.68% | Nov 5, 2024 |
| JMP Securities | JMP Securities | Buy Maintains $15 → $16 | Buy | Maintains | $15 → $16 | +111.36% | Aug 6, 2024 |
| Barclays | Barclays | Hold Maintains $6 → $7 | Hold | Maintains | $6 → $7 | -7.53% | Aug 6, 2024 |
Financial Forecast
Revenue This Year
457.39M
from 331.41M
Increased by 38.01%
Revenue Next Year
544.48M
from 457.39M
Increased by 19.04%
EPS This Year
-0.38
from -1.18
EPS Next Year
-0.08
from -0.38
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 476.7M | 577.5M | 697.7M | |||
| Avg | 457.4M | 544.5M | 625.8M | |||
| Low | 436.5M | 496.2M | 553.7M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 43.8% | 26.3% | 28.1% | |||
| Avg | 38.0% | 19.0% | 14.9% | |||
| Low | 31.7% | 8.5% | 1.7% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -0.32 | 0.12 | 0.57 | |||
| Avg | -0.38 | -0.08 | 0.29 | |||
| Low | -0.45 | -0.26 | -0.07 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.